Adicet Bio Management

Management criteria checks 2/4

Adicet Bio's CEO is Chen Schor, appointed in Sep 2020, has a tenure of 4.25 years. total yearly compensation is $5.97M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $123.59K. The average tenure of the management team and the board of directors is 3.9 years and 3.6 years respectively.

Key information

Chen Schor

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage10.1%
CEO tenure4.3yrs
CEO ownership0.2%
Management average tenure3.9yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Jul 12
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio: Microcap With A High Risk To Reward Ratio

May 23

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01
Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Dec 07
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Aug 07
Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Apr 20
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16
Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18
We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

CEO Compensation Analysis

How has Chen Schor's remuneration changed compared to Adicet Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$118m

Jun 30 2024n/an/a

-US$137m

Mar 31 2024n/an/a

-US$140m

Dec 31 2023n/an/a

-US$143m

Sep 30 2023n/an/a

-US$143m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$4mUS$562k

-US$70m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

-US$48m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$10mUS$536k

-US$62m

Sep 30 2021n/an/a

-US$55m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$11mUS$499k

-US$37m

Compensation vs Market: Chen's total compensation ($USD5.97M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Chen's compensation has increased whilst the company is unprofitable.


CEO

Chen Schor (52 yo)

4.3yrs

Tenure

US$5,973,807

Compensation

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...


Leadership Team

NamePositionTenureCompensationOwnership
Chen Schor
CEO, President & Director4.3yrsUS$5.97m0.16%
$ 123.6k
Aya Jakobovits
Founder & Independent Directorno dataUS$240.29k1.04%
$ 784.9k
Brian Harvey
Chief Financial Officer4.3yrsUS$2.13m0.068%
$ 51.4k
Donald Healey
Chief Technology Officer4.2yrsUS$2.09m0.043%
$ 32.3k
Blake Aftab
Senior VP & Chief Scientific Officer3.7yrsUS$2.48m0.031%
$ 23.3k
Amy Locke
Chief Human Resource Officer2.9yrsno datano data
Nancy Boman
Senior VP & Chief Regulatory Officer2.1yrsno datano data

3.9yrs

Average Tenure

62yo

Average Age

Experienced Management: ACET's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Chen Schor
CEO, President & Director4.3yrsUS$5.97m0.16%
$ 123.6k
Aya Jakobovits
Founder & Independent Director4.3yrsUS$240.29k1.04%
$ 784.9k
Carl Gordon
Independent Chairman4.3yrsUS$275.29k0.0072%
$ 5.4k
Steve Dubin
Independent Director4.3yrsUS$254.29k0.013%
$ 10.0k
Andrew Sinclair
Independent Director3.8yrsUS$255.29k0.0072%
$ 5.4k
Jeffrey Chodakewitz
Independent Director4.3yrsUS$240.29k0.0072%
$ 5.4k
Marco Davila
Member of Scientific Advisory Board3.4yrsno datano data
Lloyd Klickstein
Directorless than a yearUS$2.90m0.12%
$ 94.1k
Michael Kalos
Member of Scientific Advisory Board3.4yrsno datano data
Saul Priceman
Member of Scientific Advisory Board3.4yrsno datano data
Constantine Mitsiades
Member of Scientific Advisory Board3.4yrsno datano data
Alice Bertaina
Member of Scientific Advisory Board3.4yrsno datano data

3.6yrs

Average Tenure

67yo

Average Age

Experienced Board: ACET's board of directors are considered experienced (3.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adicet Bio, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Yatin SunejaGuggenheim Securities, LLC